Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Clinical Strategies in the Testing of Thyroid Function Revised by Jim Stockigt, 26 March 2004 1. WHO SHOULD BE TESTED FOR THYROID DYSFUNCTION? The clinical manifestations of thyrotoxicosis (hyperthyroidism), or hypothyroidism are so diverse that diagnosis based on clinical features alone lacks both sensitivity and specificity. Hence, reliance is placed on measurements of circulating thyroid hormones and thyroid stimulating hormone (TSH) to confirm or rule out thyroid dysfunction (TD). Guidelines from the American College of Physicians in 1998 (1, 2) for the detection of TD now recommend routine measurement of TSH in women over 50, the group most likely to have overt or subclinical thyroid dysfunction. It should be noted that testing is advocated at the time of presentation for medical care, ie a case finding strategy, rather than screening of the whole population group. This approach depends on the application of TSH assays sufficiently sensitive to detect the earliest stages of either thyrotoxicosis or primary hypothyroidism. A normal serum TSH value in ambulatory patients without associated disease or pituitary dysfunction has a high negative predictive value in ruling out both primary hypothyroidism and thyrotoxicosis (1, 2), which suggests that free T4 need only be routinely estimated if TSH is abnormal. However, it should be noted that this TSH first?strategy of thyroid function testing has definite limitations (see below). After a normal TSH value, re-testing is probably not required for 5 years (3). Recent American Thyroid Association guidelines (4) extend these indications to recommend that all adults have their serum TSH concentrations measured, beginning at age 35 and every 5 years thereafter. The benefits from this approach, particularly in males, remain to be demonstrated. In some groups (table 1), known to be at increased risk of TD, there is a case for routine testing even in the absence of suggestive clinical features. Table 1. Groups with an increased likelihood of thyroid dysfunction Previous thyroid disease or surgery Goitre Associated autoimmune disease(s) (4a) Diabetes mellitus, type 1 (5, 5a) Previous postpartum thyroid dysfunction (6) Down's syndrome (7) Turner 抯 syndrome (7a) Chronic renal failure (7b) Irradiation of head and neck (8, 8a) Radical laryngeal/pharyngeal surgery Recent Cushing's syndrome (9, 9a) Environmental irradiation ? (9b) Thalassemia major (9c) Primary pulmonary hypertension (9d) Polycystic ovarian syndrome (9e) Drug therapy Amiodarone (10) Lithium (11, 11a) Thalidomide (11c) Biological agents Interferon (12) Ribavirin (12a) Interferon (13) Interleukin 2 (14) Therapeutic use of antibodies (15) Growth hormone treatment (15a) Pituitary surgery or irradiation (15b) Severe head injury (16) Very low birth weight premature infants (17, 18) Almost all developed countries now have routine neonatal screening programs for congenital hypothyroidism using heel prick filter paper blood spots (see chapter 15). The value of such programs is clear (19), but it is notable that neonatal screening is not yet routine in numerous developing countries where the prevalence of neonatal hypothyroidism may be high, often associated with iodine deficiency (20). In terms of clear benefit from allocation of health care resources in developing countries, the establishment of neonatal screening (20a) should probably take precedence over routine testing of adults. Based on recent evidence of significant intellectual impairment in the offspring of women who were even mildly hypothyroid early in pregnancy (21), testing of thyroid function may soon become standard practice as early as possible in pregnancy, or in women who intend to become pregnant. Early diagnosis and treatment are crucial, because foetal brain development in the first trimester is influenced by maternal thyroid function and follow-up studies indicate significant intellectual impairment in the offspring of women who were mildly hypothyroid during pregnancy (22,22a)The case for routine testing of thyroid function early in pregnancy would be further reinforced by confirmation of the finding of about 4-fold increase in fetal death in women found to have serum TSH >6 mU/l in the second trimester of pregnancy (23). The arguments for and against screening for autoimmune thyroid diseases (5) and postpartum TD in particular (24) have been debated in detail. An increased prevalence of features of thyroid autoimmunity has been reported in infertile women, particularly those with endometriosis (24a), and in women who have recurrent miscarriages (24b), but benefits from correction of subclinical thyroid dysfunction have yet to be demonstrated. 1.1. The basis for a case-finding strategy Routine laboratory testing of particular population groups becomes well founded if a testing strategy satisfies the following criteria: a. An abnormality cannot be identified in a reliable and timely way by standard clinical assessment. b. Dysfunction is sufficiently common to justify routine testing, either by case finding or by population screening. c. There are adverse consequences of failure to identify dysfunction, including the possibility of progression towards more severe disease. d. The laboratory test method is cost-effective and sufficiently sensitive and specific to identify those at risk of adverse consequences. e. There are no major adverse consequences of testing f. Treatment is safe and effective and prevents some or all of the adverse consequences. g. Abnormal findings from screening or case-finding can be adequately followed-up to ensure an appropriate clinical response. An early detection program may be of little value if this last requirement cannot be met. While the first five of the above criteria are reasonably firmly established, there is at best only weak evidence to support the final two requirements. The strength of evidence for benefit from intervention in subclinical thyroid dysfunction has recently been reviewed (24c, 24d). Despite reasonable evidence to link subclinical thyroid dysfunction to potential adverse consequences, long-term studies will be required to establish whether intervention improves mortality or quality of life. 1.2. Sensitivity and accuracy of clinical assessment Studies of unselected patients evaluated by primary care physicians show that clinical acumen alone lacks both sensitivity and specificity in detecting previously undiagnosed TD. In two Scandinavian studies of over 3000 unselected patients who were assessed by both clinical and laboratory criteria, a thyroid disorder was not suspected by primary care physicians in over 90% of those who tested positive, even when clinical features were apparent in retrospect (25, 26). Furthermore, in up to one-third of patients evaluated for suspected thyroid dysfunction by specialists, laboratory results lead to revision of the clinical assessment (27). Systematic comparison of the standard clinical features of hypothyroidism with laboratory tests (28) showed that clinical assessment identified only about 40% with overt hypothyroidism and that classical signs were present only in patients with severe overt hypothyroidism. During the post-partum period, TD could not be reliably identified from clinical features (6). There is some recent controversy on the relative value of clinical and laboratory evaluation of thyroid function. O'Reilly (29) has expressed the view that the clinical criteria are being side-lined, while biochemical assessments lack specificity. However, this author considered TSH and T4 individually, rather than in the feedback relationship between trophic hormone and target gland product that is fundamental to endocrine diagnosis (see below). In response to his position, several authorities emphasised the lack of sensitivity of clinical features in detecting TD, while conceding that optimal assessment requires both clinical and laboratory input (30, 31). Both overt thyrotoxicosis and hypothyroidism can have important consequences before the usual clinical features are obvious, and clinicians often fail to recognize diagnostic features even when they are present (25, 26). Thus, it may be no more valid to wait for recognition of clinical features before considering a diagnosis of thyroid dysfunction, than to rely on thirst and polyuria for diagnosis of diabetes. Clinical evaluation remains of central importance to assess the severity of TD, evaluate discordant results, establish the specific cause of TD and monitor the response to treatment. There is little doubt that repeated laboratory confirmation of normal thyroid function is wasteful; several strategies have been suggested to improve cost-effectiveness (32, 33). 1.3. Prevalence In considering the prevalence of thyroid dysfunction, a distinction needs to be made between so-called subclinical and overt abnormalities; a distinction that is based on laboratory rather than clinical criteria. The term 'subclinical' has been used when the serum concentration of TSH is persistently abnormal, while the concentrations of T4 and T3 remain within their reference intervals. There is a trend to replace the term 'subclinical hypothyroidism' with the designation 'mild thyroid failure' (33a) because of accumulating evidence that TSH excess alone is accompanied by tissue evidence of thyroid hormone deficiency (see below). In the progressive development of TD, abnormal values for serum TSH generally occur before there is a diagnostic abnormality of serum T4, because of non-linearity of the negative feedback relationship between serum T4 and release of TSH from the anterior pituitary. For a two-fold change in serum T4 up or down from the setpoint for that individual, the serum TSH will normally change up to 100-fold in the reverse direction (34, 35). Thus, TSH may be recognisably abnormal months or years before there is a diagnostic change in the serum concentrations of T4 or T3. The more widespread the testing of thyroid function in the absence of suggestive clinical features, the greater the proportion of abnormal results that indicate mild TD in which only TSH is abnormal. In evaluating serum TSH, typically defined with a normal reference interval of about 0.4-4.0 mU/l, it is important to note that normal values are logarithmically distributed, with mean and median values at 1.0-1.5 mU/l (36, 37). While values of 2-4 mU/l lie within the reference range, the likelihood of eventual hypothyroidism may increase progressively for values above 2 mU/l, especially if thyroid peroxidase antibody is positive (38). The Whickham study, first reported in 1977 from an iodine replete region in Northern England (39), showed a prevalence of 1.9 -2.7 % overt thyrotoxicosis and 1.4 -1.9% overt hypothyroidism in women, with progressive increase with age; prevalence in males was much lower. Estimates of 'subclinical' dysfunction were 4-5 fold higher, with about 10% of women over 50 showing an increase in serum TSH, again with progressive increase with age (39). The subsequent 20 year follow up of this cohort showed an incidence of spontaneous hypothyroidism of about 3.5/1000 subjects/year in females and 0.6/1000/year in males (38). The equivalent figures for thyrotoxicosis were 0.8/1000/year and <0.1/1000/year. In women, the likelihood of developing hypothyroidism increased with age and was augmented about 8-fold if either thyroid peroxidase antibody (TPOAb) was positive, or if serum TSH had been increased in the initial study; the risk rose almost 40-fold if both were abnormal (38). A population study in Colorado (40), of over 25, 000 individuals of mean age 56 years, 56% of whom were female, showed TSH excess in 9.5 %, with a 2.2 % prevalence of suppressed TSH; over half the group with suppressed TSH were taking thyroid medication. In women, the prevalence of TSH excess increased progressively from 4% at age 18-24 to 20% over age 74 (40). The National Health and Nutrition Examination Survey (NHANES III) (40a), found hypothyroidism in 4.6% of the US population (0.3% overt and 4.3% subclinical) and hyperthyroidism in 1.3% (0.5% overt), with increasing prevalence with age in both females and males (figure 1). Abnormalities were more common in females than in males. The prevalence of positive thyroid peroxidase was clearly associated with both hyper- and hypothyroidism, but there were important ethnic differences in antibody prevalence. Figure 1 Percentage of the US population with abnormal serum TSH concentrations as a function of age. The disease-free population excludes those who reported thyroid disease, goiter or thyroid-related medications; the reference population excluded, in addition, those who hadpositive thyroid autoantibodies, or were taking medications that can influence thyroid function. Note the much higher prevalence of TSH abnormalities in the total population, than in the reference population. (from reference 24a) The prevalence of thyroid dysfunction is also high when younger women are tested during the post-partum period (41). In an Australian study, 11.5% of women showed at least one laboratory abnormality of thyroid function when tested 6 months after delivery (42). TSH values were increased in 6%, of whom almost 90% showed positive TPOAb, indicating an autoimmune abnormality. In about half the women with initial TSH elevation who had not been treated, TSH was still increased 30 months after delivery (6), consistent with several studies that show an increased prevalence of late hypothyroidism after postpartum dysfunction (41). These findings clearly demonstrate that women with postpartum hypothyroidism should be followed to allow early detection of later overt hypothyroidism (6, 41). It remains uncertain whether long-term treatment is justified on the basis of the initial finding (6,41), but there are clearly important implications of untreated maternal hypothyroidism for fetal development in subsequent pregnancies (22,22a). Prevalence data from one region do not necessarily apply in other populations, because of differences such as ethnic predispositionor variations in iodine intake. For example, in Hong Kong, where iodine intake is marginally deficient, only 1.2% of Chinese women aged over 60 years had serum TSH values > 5mU/l, with a comparable prevalence of suppressed values indicating possible thyrotoxicosis (43). Several European studies (44, 45) have compared the effect of various levels of iodine intake on the prevalence of thyroid over- and underfunction. Hypothyroidism is generally more common with abundant iodine intake, while goitre and subclinical thyrotoxicosis are more common with low iodine intake (44, 45). These regional differences may influence the choice of diagnostic test and target population. For example, in an iodine replete environment, emphasis could be placed on testing younger or pregnant women for subclinical hypothyroidism by measurement of TSH and peroxidase antibody, whereas in an iodine-deficient region there might be additional emphasis on early detection of thyroid autonomy and thyrotoxicosisin older people, using a highly sensitive TSH assay. 1.4. Adverse consequences of thyroid dysfunction Before reliable tests of thyroid function became widely available, severe thyrotoxicosis and hypothyroidism were sometimes life-threatening disorders, but thyroid storm or myxoedema coma now have become uncommon, a change that is probably the result of widespread diagnostic testing in clinical practise. Elderly patients with previously unrecognised overt primary hypothyroidism probably have much to gain from a case-finding approach at the time of presentation for medical care. For example, numerous complex management issues may arise when elderly patients with uncorrected severe hypothyroidism are admitted to hospital for emergency procedures (46). Factors that adversely influence outcome include abnormal sensitivity to anaesthetic agents, sedatives, analgesics and narcotics, as well as anemia, hypoventilation, hyponatremia and impaired temperature regulation (46). In addition to the benefits of early identification of undiagnosed overt TD, widespread diagnostic testing can be justified on the basis of evidence that mild or 'subclinical' dysfunction has adverse consequences. The issues that identify the clinical importance of subclinical TD are summarised in table 2; many of these adverse effects relate to the cardiovascular system, as recently reviewed ( 47, 48). There is some evidence that mild thyroid abnormalities may influence mortality. A survey of the relationship between serum TSH and all-cause and cardiovascular mortality over a 10 year period in individuals over 60, showed that the group with serum TSH below 0.5 mU/l, had a significantly increased mortality, apparently due to cardiovascular disease (49), although an increased serum TSH was not associated with excess mortality (49). It is not yet known whether suppression of TSH to the levels (<0.03 mU/l) typical of thyrotoxicosis would be associated with a more marked effect on mortality. Table 2. Reported adverse effects of subclinical thyroid dysfunction Subclinical thyrotoxicosis (suppressed TSH, normal free T4, normal free T3) Exposure to iodine may precipitate severe thyrotoxicosis (50) Threefold increased risk of atrial fibrillation after 10 years (51) Abnormalities of cardiac function (52, 53) Osteoporosis risk increased (54, 55) Progression to overt thyrotoxicosis (56,65) Subclinical hypothyroidism or mild thyroid failure (increased TSH, normal free T4) Non specific symptoms may improve with treatment (57,58,63a) Progression to overt hypothyroidism (38,59) Independent risk factor for atherosclerosis? (60) Adverse effects on vascular compliance (61) Abnormal cardiac function may improve with treatment (62) Beneficial effect of treatment on lipids (63,63a) Adverse effect on foetal brain development in pregnancy (21,22,22a) Increased prevalence of depressive illness ? (64) Impaired fibrinolysis (64a) 1.4.1 Thyrotoxicosis 1.4.1.1 Progression of subclinical to overt thyrotoxicosis Follow up studies suggest that spontaneous progression to overt thyrotoxicosis is uncommon and that subnormal detectable levels of TSH in the range 0.05-0.4 mU/l frequently return to normal within one year ( 65). By contrast, undetectable TSH values normalize infrequently, but the chance of spontaneous progression to overt thyrotoxicosis appears to be < 10% per year ( 56,65). 1.4.1.2 Cardiac effects From the Framingham study it was found that undetected subclinical thyrotoxicosis, defined only by suppression of TSH, carried a three-fold increased risk of atrial fibrillation within 10 years ( 51). As yet, there is no study that shows that treatment given on the basis of low TSH alone, modifies this risk, although it is clear that survival is adversely affected by atrial fibrillation ( 66). Other cardiac consequences of subclinical thyrotoxicosis have been documented in patients receiving suppressive doses of T4 for differentiated thyroid cancer. Prevalence of atrial premature beats is increased, as is left ventricular mass index, associated with higher values for fractional shortening and velocity of shortening ( 52). Impaired left ventricular ejection fraction and reduced exercise capacity have been documented in this group and can be alleviated by beta blockade ( 53). 1.4.1.3 Iodine-induced thyrotoxicosis Undiagnosed subclinical thyrotoxicosis due to autonomous nodular thyroid disease, a condition especially prevalent in iodine deficient regions, carries the risk of progression to severe overt thyrotoxicosis after iodine exposure ( 67). An Australian study from a region that is not known to be iodine deficient, was suggestive of recent iodine exposure, most often from radiologic contrast agents, in up to 25% of elderly thyrotoxic patients ( 50). Prior knowledge of subnormal serum TSH suggests thyroid autonomy in this high risk group in whom iodine exposure should be avoided because of the risk of severe iatrogenic thyrotoxicosis. 1.4.1.4 Osteoporosis While longstanding overt thyrotoxicosis is an important risk factor for osteoporosis, the association has until recently been less clear for subclinical thyrotoxicosis. Overt thyrotoxicosis is associated with reduced bone density, predominantly affecting cortical rather than trabecular bone, so that the femoral neck is more affected than the lumbar spine, associated with an increase in fracture rate ( 68). In postmenopausal women, either treated with T4 sufficient to suppress TSH, or with subclinical thyrotoxicosis due to multinodular goitre, there is a decrease in mean bone density and an increase in urinary excretion of pyridinoline cross links ( 69). It has now been shown that women over 65 with suppressed TSH are at increased risk of hip and vertebral fractures ( 55). Notably, in a recent controlled trial of suppressive T4 treatment for multinodular goitre, TSH suppression without clear excess of serum T4 or T3 was shown to result in a mean 3.6% decrease in lumbar spine density within 2 years ( 54). 1.4.2 Hypothyroidism 1.4.2.1 Progression of subclinical (or mild) hypothyroidism to overt deficiency The benchmark study of thyroid epidemiology from Wickham, UK,(38), showed that the likelihood of overt hypothyroidism after 20 years was directly related to the initial serum TSH, even when that value was in the range 2-4 mU/l, within the upper reference interval. Huber et al (59) followed 82 Swiss women with subclinical hypothyroidism, with normal free T4 and serum TSH > 4 mU/l, for a mean of 9.2 years (figure 2). About half of their cohort had had previous ablative treatment for Graves?disease. The cumulative incidence of overt hypothyroidism, defined as low free T4 with TSH > 20 mU/l, was directly related to the initial serum TSH, with 55% of women with initial serum TSH >6 mU/l progressing to overt hypothyroidism. Progression was not uniform, and over half of the cohort showed no deterioration of thyroid function. Positive microsomal antibodies increased the likelihood of progression in both studies. Figure 2 Kaplan Meier estimates of the cumulative incidence of overt hypothyroidism in women with subclinical hypothyroidism (initial serum TSH > 4mU/l) as a function of initial serum TSH, thyroid secretory reserve in response to oral TRH and detectable microsomal antibody. Serum TSH appears to be the strongest of these predictors. (from reference 59) 1.4.2.2 Atherosclerosis Subclinical hypothyroidism, or mild thyroid failure, was shown to be an independent risk factor for both myocardial infarction and radiologically-visible aortic atherosclerosis in a recent study of Dutch women over 55 years of age (60). This effect was independent of body mass index, total and HDL cholesterol, blood pressure and smoking status. The attributable risk for subclinical hypothyroidism was comparable to that for each of the major risk factors, hypercholesterolemia, hypertension, smoking and diabetes mellitus. The association was slightly stronger when subclinical hypothyroidism was associated with TPOAb, but thyroid autoimmunity itself was not an independent risk factor. 1.4.2.3 Vascular compliance The finding of impaired flow-mediated, endothelium-dependent vasodilatation even in subjects with borderline hypothyroidism or high-normal serum TSH values is of potential importance (61). Baseline artery diameter and forearm flow were comparable, but flow mediated vasodilatation during the period of reactive hyperemia was significantly impaired even in the group with serum TSH of 2-4 mU/l, compared with the group with serum TSH 0.4-2 mU/l. The difference could not be attributed to a difference in maximal nitrate-induced vasodilatation, age, sex, hypertension, diabetes, smoking, serum cholesterol, or levels of total T3 and T4. This finding suggests that even minor deviation from an individual's pituitary-thyroid set point may be associated with alteration in vasodilatory response. There is no known direct action of TSH that would account for this effect. 1.4.2.4 Cardiac function From echocardiographic studies, there is evidence that mild thyroid failure can significantly increase systemic vascular resistance and impair cardiac systolic and diastolic function, as demonstrated by decreased flow velocity across the aortic and mitral valves (48). These changes, which were associated with reduced cardiorespiratory work capacity during maximal exercise, were reversed by T4 treatment sufficient to normalize serum TSH (48). Impairment of both diastolic and systolic function was demonstrable by echocardiography in a subclinically hypothyroid group of patients with TSH in the range 4-12 mU/l (62). Thyroxine treatment sufficient to normalise TSH to a mean of 1.3 mU/l. for 6 months was associated with improvement in myocardial contractility (62). It remains to be established how these reversible abnormalities relate to cardiovascular prognosis. 1.4.2.5 Lipids Overt hypothyroidism is associated with a well known increase in the serum cholesterol concentration and correction of overt hypothyroidism results in a decrease in total and LDL cholesterol, apolipoprotein A1, apo B and apo E, while serum triglyceride concentrations may also decrease (70). A defect in receptor-mediated LDL catabolism, similar to that seen in familial hypercholesterolaemia, has been described in severe overt hypothyroidism (71), but there is no evidence to support such an abnormality in mild thyroid failure. The Colorado study of over 25,000 subjects showed a continuous graded increase in serum cholesterol over a range of serum TSH values from <0.3 to >60 mU/l (40). However, there is still no consensus that mild thyroid failure has an adverse effect on plasma lipids, or that T4 treatment sufficient to normalize isolated TSH excess has a beneficial effect. A recent meta analysissuggests that T4 treatment of subjects with mild thyroid failure does lower the mean total and LDL cholesterol, and is without effect on HDL cholesterol or triglyceride (63). In a prospective double-blind, placebo-controlled trial of thyroxine in subclinical hypothyroidism in which the response was carefully monitored with TSH, Meier et al (63a) reported that the decrease in LDL cholesterol was more pronounced with higher initial TSH levels >12 mU/l or with elevated baseline LDL concentration. It remains uncertain whether the serum concentration of the highly atherogenic Lp(a) particle is increased in overt hypothyroidism and whether T4 treatment sufficient to normalize TSH has a favourable influence. Serum concentrations of Lp(a) have been found to be increased in overt hypothyroidism with normalization after treatment in some studies (72, 73 ) while others fail to confirm this finding (63a,74,75). 1.4.2.6 Neurobehavioural effects It is well known that overt TD may present with psychological or psychiatric symptomatology. A small retrospective study has shown a 2-3 fold increased frequency of previous depression in subjects with mild thyroid failure (64), while T4 treatment has been reported to improve neuropsychological responses in this group (76). If these findings can be confirmed by studies that include appropriate control groups, it would be justified to conclude that even mild thyroid failure has potentially reversible effects on neuropsychiatric status. 1.5. Effectiveness of laboratory assays for case finding and screening 1.5. TSH reference intervals If the diagnosis and classification of patients with potential thyroid disease is to based on serum TSH, there should be consensus on the reference intervals for this parameter, but consensus has not yet been achieved, for a variety of epidemiological and semantic reasons. The upper limit of the normal range?for serum TSH is dependent on the analytical method and on the study population that is selected (77), in particular, whether subjects with positive peroxidase antibody are excluded. It remains uncertain whether apparent ethnic differences reflect the prevalence of mild thyroid dysfunction in those populations (40a). Serum TSH values within the upper normal statistical reference range are associated with an increased chance of long-term hypothyroidism (38), but an arbitrary lowering of the upper limit will decrease the specificity and predictive value of serum TSH as a first-line test. The sensitivity of current assays identifies a substantial population whose serum TSH values are statistically subnormal, in the range 0.1-0.45 mU/l; these subnormal-detectable values are clearly different from those typical of thyrotoxicosis. There is currently lack of consensus as to how such intermediate TSH values should be classified. The NHANES III study (40a) reserves the designation subclinical hyperthyroidism?for serum TSH values <0.1 mU/l. By contrast, recent guidelines for the diagnosis and management of subclinical thyroid disease classify values below the lower normal limit of 0.45 mU/l as indicating subclinical hyperthyroidism (24c, 24d), while making more limited recommendations for the management of the intermediate group in the range 0.1-0.45 mU/l. Such a difference in classification will probably affect over 1% of the population. Since the gradation from normality to severe thyroid dysfunction is a continuum, studies of adverse outcomes or benefits from intervention will be critically dependent on precise uniform terminology. 1.5.2 Choice of initial test The definitive diagnosis of TD should always be made using the typical relationships between trophic hormone and target gland secretion that define endocrine dysfunction (35, 37). In contrast, case-finding studies generally begin with a single test. Previous discussion about the relative value of TSH and T4 measurements as single initial tests has swung in favour of TSH because of its superior sensitivity in detecting the earliest stages of TD (3). Thus, assessment of untreated subjects now often begins with measurement of TSH alone, with T4 and T3 assays added only if TSH is abnormal, or if an abnormality of TSH secretion is suspected. It is self-evident that serum TSH loses its diagnostic value when pituitary function is abnormal ( 78); serum T4 then becomes the front-line test. In the absence of associated disease, a normal serum TSH concentration by a so-called third generation assay (a functional lower limit of sensitivity of about 0.01 mU/l), has high negative predictive value in ruling out primary hypothyroidism and thyrotoxicosis. Such immunometric assays, which use two antibodies against different epitopes of the TSH molecule, give a wide separation between the lower limit of the normal reference range at about 0.4 mU/l and the typical TSH values that are found in thyrotoxicosis. It remains uncertain whether values in the subnormal detectable range merit the designation subclinical thyrotoxicosis? , . While some subjects with borderline-low TSH values do progress to overt thyrotoxicosis, values in this range may also revert to normal ( 56,65) . Danese et al (3) analysed the cost-effectiveness of TSH measurement, performed every 5 years from the age of 35 and concluded that for females, such a strategy compared favourably with other preventative medical practices (3). From age 35, the cost per quality-adjusted life year was about US$9000 for females and $22500 for males, but this cost dropped by half if testing was commenced from age 65. Cost effectiveness was highly dependent on the price of the TSH assay and was adversely affected by more frequent testing (3). There are some clinical situations in which assessment of thyroid function will give a high prevalence of abnormalities that cannot be interpreted with certainty. Notably, glucocorticoids and dopaminergic agents have a potent effect to suppress TSH secretion ( 79), while TSH is also frequently subnormal in starvation or caloric deprivation ( 80). Transient increases to above normal can occur in euthyroid subjects during recovery from critical illness ( 81). The finding that 33% of serum TSH values fell more than 2 SD from the geometric mean in acutely hospitalized patients, while 17 % of values were more than 3 SD from the mean value, suggests that an abnormal TSH value lacks diagnostic specificity in this setting ( 82). A serum free T4 estimate will generally follow from an abnormal TSH value, but during critical illness, free T4 estimates often show non-specific abnormalities ( 83) (see section 4.3, below). This lack of specificity is the basis for a recommendation against routine assessment of serum TSH and free T4 during acute critical illness in the absence of risk factors, or clinical features suggestive of a thyroid disorder ( 84). Testing of thyroid function is appropriate in a wide range of psychiatric disorders, but diagnostic specificity is limited by a high prevalence of transient non-specific abnormalities at the time of acute psychiatric admission ( 85). Thus, it has been recommended that laboratory evaluation should be delayed for 2-3 weeks after acute presentation, unless there are specific risk factors for TD ( 86). 1.6. Potential adverse effects of testing In terms of potential for adverse effects, there may be important differences between screening of unselected populations and the case-finding strategy that is now recommended for TD There are no reports of a "labelling effect" (i.e. perception of chronic illness in previously asymptomatic subjects), described in hypertension screening programs ( 87), when testing for TD is done at the time of presentation for medical care. Nevertheless, further attention needs to be given to the potential for unwarranted treatment based on false positive results, as well as the cost of follow-up investigations for perceived abnormalities that may not warrant treatment at any stage. . In particular, there is a need for clinical consensus as to how marginally abnormal results should be classified. Widespread laboratory testing will lead to an increase in the number of false positive results and the potential for a diagnostic method to give misleading variations from normal may not become known for some years until the full diversity of the non-diseased population is documented ( 88). 1.7 Safety and effectiveness of treatment The benefits of early diagnosis and treatment are self-evident from the obvious decline in hospitalisation and mortality rates for severe TD over past decades. By contrast, the arguments for treating mild TD are less compelling, but the number of affected people is much larger. The points in favour of treating mild TD relate directly to the adverse consequences listed in table 2, but for most of these potential adverse outcomes there is still a lack of long-term studies that show benefit. On the basis of potential benefit from simple straightforward treatment and freedom from adverse effects, the argument for active treatment is generally stronger for mild thyroid failure than for subclinical thyrotoxicosis. Conservative T4 therapy aimed at normalising TSH is simple, inexpensive and generally safe ( 89), although replacement may not be warranted in the extremely elderly. Where cardiovascular disease precludes full thyroid hormone replacement, detailed evaluation of the cardiac abnormality is appropriate. In contrast, treatment of subclinical thyrotoxicosis needs to be evaluated in relation to drug side-effects and potential for hypothyroidism. 1.8. Follow-up of abnormal results If serum TSH is used as a single initial test for case-finding, a value outside the reference interval should lead to estimation of serum free T4 on the same sample, if possible without further request or recall of the patient. This requires an algorithm-based testing protocol, which should also include measurement of serum free T3 if TSH is suppressed, in order to identify T3 toxicosis. It may also be relevant to measure TPOAb if TSH is increased to define an autoimmune mechanism of hypothyroidism, particularly as a raised level of this antibody is associated with an increased likelihood of progression to overt hypothyroidism (38 For screening or case-finding to be effective, patients with unsuspected overt TD should be actively traced because they will benefit most from treatment and have the most to lose if the abnormal finding is ignored. For mild TD, a practitioner who has continuing contact with the patient should correlate the assay results with the clinical presentation and initiate the necessary follow-up. However, there is currently no consensus as to how an appropriate clinical response to abnormal laboratory findings can be assured A transition towards identification of TD by laboratory measurement, rather than on clinical criteria ,modifies, but in no way diminishes the clinician's role. An abnormal laboratory finding must be placed in context, and an assessment needs to be made of the cause of the abnormality and its severity., The severity of thyroid dysfunction cannot be judged from the extent of the laboratory abnormality (89a), which indicates neither the duration of exposure, nor individual susceptibility. A result that may lead to lifelong replacement therapy should be discussed in detail with the patient. Whether a decision is made to treat or to observe, patient education is crucial in establishing effective compliance and rational cost-effective follow-up. Computer based programs can identify affected individuals, but these programs cannot replace direct involvement of a clinician. There may be potential medicolegal consequences of failure to respond to abnormal results, if widespread laboratory testing is initiated without an established follow-up plan. 1 American College of Physicians. Screening for thyroid disease. Ann Intern Med 1998;129:141-3. 2 Helfand M, Redfern CC. Screening for thyroid disease: an update. Ann Intern Med 1998;129:144-58. 3 Danese MD, Powe NR, Sawin CT, et al. Screening for mild thyroid failure at the periodic health examination. JAMA 1996;276:285-92. 4 Ladenson PW, Singer PA, Ain KB et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med 2000;160:1573-5. 4a Jenkins RC, Weetman AP. Disease associations with autoimmune thyroid disease. Thyroid 2002;11:977-88. 5 Tunbridge WMG, Vanderpump MPJ. Population screening for autoimmune thyroid disease. Endocrinol Metab Clin N Am 2000; 29:239-53. 5a Hansen D, Bennedbaek FN, Hoier-Madsen M et al. A prospective study of thyroid function, morphology and autoimmunuty in young patients with type I diabetes Eur J Endocrinol. 2003; 148:245-51. 6 Stuckey BGA, Kent GN, Allen JR et al The biochemical and clinical course of postpartum thyroid dysfunction: the treatment decision. Clin Endocrinol 2001;54:377-83. 7 Kennedy RL, Jones TH, Cuckle HS. Down's syndrome and the thyroid. Clin Endocrinol 1992;37:471-6. 7a Elshiekh M, Wass J, Conway GS. Autoimmune thyroid syndrome in women with Turner 抯 syndrome - the association with karyotype. Clin Endocrinol. 2001;55:223-6. 7b Kaptein EM Thyroid hormone metabolism and thyroid diseases in chronic renal failure Endocrine Reviews 1996; 17: 45-63. 8 Sinard RJ, Tobin EJ, Mazzaferri EL, et al. Hypothyroidism after treatment for nonthyroid head and neck cancer. Arch Otolaryngol Head Neck Surg 2000;126:6528a Sklar C, Whitton J, Mertens A et al Abnormalities of the thyroid in survivors of Hodgkin 抯 disease: data from a childhood cancer survivor study J Clin Endocrinol Metab 2000; 85: 3227-32. 9 Colao A, Pivonello R, Faggiano A, et al. Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol 2000;53:13-9. 9a Niepomniszczse H, Pitoia F, Katz SB et al. Primary thyroid disorders in endogenous Cushing 抯 syndrome. Eur J Endocrinol. 2002; 147:305-11 9b Eheman CR, Garbe P, Tuttle RM, Autoimmune thyroid disease associated with environmental thyroidal irradiation Thyroid 2003;13:453-64. 9c Zervas A, Katapodi A, Protonotariou A et al. Assessment of thyroid function in two hundred patients with ?-thalassemia major. Thyroid 2002;12:151-4 9d Chu JW, Kao PN, Faul Jl et al. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension Chest 2002; 122: 1668-73. 9e Janssen OE, Mehlmauer N, Hahn S et al. High prevalence of autoimmune thyroiditis in patients with polycystic ovarian syndrome Eur J Endocrinol 2004; 150: 363-9. 10 Trip MD, Wiersinga WM, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991;91:507-11. 11 Johnston AM, Eagles JM. Lithium-associated clinical hypothyroidism Br J Psychiat 1999; 175; 336-9. 11a Miller KK, DanielsGH Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol 2001;55:501-8. 11c Badros AZ, Siegel E, Bodenner D et al. Hypothyroidism in patients with multiple myeloma treated with thalidomide Am J Med 2002; 112: 412-3. 12 Carella C, Mazziotti , Morisco F et al. Long-term outcome of interferon-?-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment J Clin Endocrinol Metab 2001;86:1925-9. 12a Carella C, Maziotti G, Morisco F et al. The addition of ribavirin to interferon-? therapy in HCV-related chronic hepatitis does not modify the thyroid autoantibody response, but increases the risk to develop hypothyroidism. Eur J Endocrinol. 2002; 146: 743-9. 13 Durelli L, Ferrero B, Oggero A et al. Thyroid function and autoimmunity during interferon ?-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001; 86: 3525-32.14 Schwartzentruber DJ, White DE, Zweig MH, et al. Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 1991;68:2384-90. 15 Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354: 1691-5. 15a Porrretti S, Giavoli C, Ronchi C et al. Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T4 therapy become mandatory? J Clin Endocrinol Metab 2002;87:2042-5. 15b Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK et al. A population-based study of thyroid function after radiotherapy and chemotherapy for a childhood brain tumor J Clin Endocrinol Metab 2003;88:136-40. 16 Benvenga S, Campenni A, Ruggieri RM et al. Hypopituitarism secondary to head trauma. J Clin Endocr Metab 2000; 85: 1353-61. 17 Rooman RP, DuCaju MVL, Op De Beeck L et al. Low thyroxinemia occurs in the majority of very preterm newborns. Eur J Pediatr 1996; 155; 211-5. 18 Fisher DL, The hypothyroxinemia of prematurity. J Clin Endocrinol Metab 1997; 82:1701-3. 19 LaFranchi S. Congenital hypothyroidism: Etiologies, diagnosis, and management. Thyroid 1999; 9:735-40. 20 Delange F. Neonatal screening for congenital hypothyroidism: results and perspectives. Hormone Res 1997; 48:51-61. 20a Bhatara V, Sankar R, Unutzer J et al A review of the case for neonatal thyrotropin screening in developing countries; the example of India Thyroid 2002 12: 591-8. 21 Smallridge RC, Ladenson PW. Hypothyroidism in pregnancy: consequences to neonatal health. J Clin Endocrinol Metab 2001; 86: 2349-53. 22 Pop VJ, Kuijpens JL, van Baar AL, et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor developments in infancy. Clin Endocrinol 1999; 50: 149-55. 22a Haddow JE, Palomaki GE, Allan WC et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child N Engl J Med 1999; 341:549-55. 23 Allan WC, Haddow JE, Palomaki GE, et al. Maternal thyroid deficiency and pregnancy complications: implications for population screening. J Med Screen 2000; 7: 127-30. 24 Amino N, Tada H, Hidaka Y, et al. Screening for postpartum thyroiditis J Clin Endocrinol Metab 1999; 84:1813-21. 24a Poppe K, Glinoer D, Van Steirteghem A et al. Thyroid dysfunction and autoimmunity in infertile women Thyroid 2002;11:997-1001. 24b Poppe K, Glinoer D, Tournaye H et al. Assisted reproduction and thyroid autoimmunity: an unfortunate combination? J Clin Endocrinol Metab 2003;88:4149-52. 24c Surks MI, Ortiz E, Daniels GH et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management JAMA 2004; 291: 228-38. 24d Col NF, Surks MI, Daniels GH. Subclinical thyroid disease: clinical applications. JAMA 2004; 291:239-43. 25 Eggertsen R, Petersen K, Lundberg P-A, et al. Screening for thyroid disease in a primary care unit with a thyroid stimulating hormone assay with a low detection limit. Br Med J 1988; 297:1586-92. 26 Petersen K. Lindstedt G. Lundberg PA, et al. Thyroid disease in middle-aged and elderly Swedish women; thyroid-related hormones, thyroid dysfunction and goitre in relation to age and smoking. J Intern Med 1991;229:407-13. 27 Jarlov AE, Nygaard B, Hegedus L et al. Observer variation in the clinical and laboratory evaluation of patients with thyroid dysfunction and goiter. Thyroid 1998;8:393-8. 28 Zulewski H, Muller B, Exer P, et al. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab 1997; 82:771-6. 29 O'Reilly DStJ. Thyroid function tests: time for a reassessment. Br Med J 2000;320:1332-4. 30 Price A, Weetman AP. Thyroid stimulating hormone outside the normal range has important implications. Br Med J 2000;321:1080. 31 Toft AD, Beckett GJ. Accurate diagnosis depends on both clinical judgement and results of tests. Br Med J 2000;321:1080-1. 32 Toubert M-E, Chevret S, Cassinat B, et al. From guidelines to hospital practice: reducing inappropriate ordering of thyroid hormone and antibody tests. Eur J Endocrinol 2000;142:605-10. 33 Schectman JM, Elinsky EG, Pawlson LG. Effect of education and feedback on thyroid function testing strategies of primary care clinicians. Arch Intern Med 1991;151:2163-6. 33a McDermott MT, Ridgway EC Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab 2001;86:4585-90. 34 Nicoloff JT, Spencer CA. The use and misuse of the sensitive thyrotropin assays. J Clin Endocrinol Metab 1990;71:553-8. 35 Ercan-Fang S, Schwartz HL, Mariash CN, et al. Quantitative assessment of pituitary resistance to thyroid hormone from plots of the logarithm of thyrotropin versus serum free thyroxine index. J Clin Endocrinol Metab 2000;85:2299-303. 36 Hershman JM, Pekary AE, Berg L, et al. Serum thyrotropin and thyroid hormone levels in elderly and middle-aged euthyroid persons. J Am Geriatr Soc 1993;41:823-8. 37 Stockigt JR. Serum TSH and thyroid hormone measurements and assessment of thyroid hormone transport. In: Braverman LE and Utiger RG, eds. Werner and Ingbar's The Thyroid, Lippincott, Williams & Wilkens, Philadelphia. 8th edn, 2000: 376-92. 38 Vanderpump MPJ, Tunbridge WMG, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol 1995;43:55-68. 39 Tunbridge WMG, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol 1977;7:481-93. 40 Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-34. 40a Hollowell JG, Staehling NW, Flanders WD et al. Serum TSH, T4 and thyroid antibodies in the United States population (1988-1994): national health and nutrition examination survey (NHANES III). J Clin Endocrinol Metab 2002;87:489-99. 41 Roti E, Uberti ED Post-partum thyroiditis ?a clinical update. Eur J Endocrinol 2002;146:275-9. 42 Kent GN, Stuckey BGA, Allen JR, et al. Postpartum thyroid dysfunction: clinical assessment and relationship to psychiatric affective morbidity. Clin Endocrinol 1999;51:429-38. 43 Kung AWC, Janus ED. Thyroid dysfunction in ambulatory elderly Chinese subjects in an area of borderline iodine intake. Thyroid 1996;6:111-4. 44 Szabolcs I, Podoba J, Feldkamp J, et al. Comparative screening for thyroid disorders in old age in areas of iodine deficiency, long-term iodine prophylaxis and abundant iodine intake. Clin Endocrinol 1997;47:87-92. 45 Aghini-Lombardi F, Antonangeli L, Martino E, et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab 1999; 84:561-6. 46 Stathatos N, Wartofsky L Perioperative management of patients with hypothyroidism Endocrinol Metab Clin N Am 2003;32:503-18. 47 Klein I, Ojamaa K. Thyroid hormones and the heart N Engl J Med 2001;344:501-9. 48 Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 2000;10:665-79. 49 Parle JV, Maissoneuve P, Sheppard MC et al. Prediction of all cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10 year cohort study. Lancet 2001; 358: 861-5. 50 Martin FIR, Tress BW, Colman PG, et al. Iodine-induced hyperthyroidism due to nonionic contrast radiography in the elderly. Am J Med 1993;95:78-82. 51 Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249-52. 52 Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993;77:334-8. 53 Biondi B, Fazio S, Cuocolo A, et al. Impaired cardiac reserve and exercise capacity in patients receiving long term thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1996;81:4224-8. 54 Wesche MFT, Tiel-v Buul MMC, Lips P, et al. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goitre. J Clin Endocrinol Metab 2001; 86: 998-1005. 55 Bauer DC, Ettinger B, Nevitt MC, et al. Risk fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001;134:561-8. 56 Stott DJ, McLellan AR, Findlayson J, et al. Elderly patients with suppressed serum TSH but normal free thyroid hormone levels usually have mild thyroid overactivity and are at increased risk of developing overt hyperthyroidism. Q J Med 1991;78:77-84. 57 Cooper DS, Halpern R, Wood LC, et al. L-thyroxine therapy in subclinical hypothyroidism. Ann Intern Med 1984;101:18-24. 58 Nystrom E, Caidahl K, Fager G, et al. A double-blind cross-over 12-month study of L-thyroxine treatment of women with 憇 ubclinical? hypothyroidism. Clin Endocrinol 1988;29:63-76. 59 Huber G , Staub J_J, Meier C et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve and thyroid antibodies J Clin Endocrinol Metab 2002; 87: 3221-6. 60 Hak AE, Pols HAP, Visser TJ et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Int Med 2000; 132:270-8. 61 Lekakis J, Papamichael C, Alevizaki M, et al. Flow-mediated, endothelium dependent vasodilatation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 1997;7:411-4. 62 Monzani F, Di Bello V, Caraccio N, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind placebo controlled study. J Clin Endocrinol Metab 2001; 86;1110-5. 63 Danese MD, Ladenson PW, Meinert CL, et al. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000;85:2993-3001 63a Meier C, Staub J-J, Roth CB et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial J Clin Endocrinol Metab 2001; 86: 4960-6. 64 Haggerty JJ, Stern RA, Mason GA, Beckwith J, Morey CE, Prange Jr AJ. Subclinical hypothyroidism: a modifiable risk factor for depression? Am J Psychiatry 1993;150:508-10. 64a Chadarevian R, Bruckert E, Leenhardt L et al. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism J Clin Endocrinol Metab 2001; 86:732-7. 65 Parle JV, Franklyn JA, Crook KW et al. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol 1991; 34:77-83. 66 Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham study. Circulation 1998; 98: 946-52. 67 Dunn JT, Semigran MJ, Delange F The prevention and management of iodine-induced hyperthyroidism and its cardiac features Thyroid 1998; 8: 101-6. 68 Ross DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994;4:319-26. 69 Guo C-Y, Weetman AP, Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol 1997;46:301-7. .70 Franklyn JA. Metabolic changes in hypothyroidism. In: Braverman LE and Utiger RG, eds. Werner and Ingbar's The Thyroid, Lippincott, Williams & Wilkens, Philadelphia. 8th edn, 2000: 833-6. 71 Thompson GR, Soutar AK, Spengel FA et al. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci USA 1981;78:2591-5. 72 De Bruin TWA, van Barlingen H, van Linde-Sibenius Trip M, et al. Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects. J Clin Endocrinol Metab 1993;76:121-6. 73 Tzotzas T, Krassas GE, Konstantinidis T, et al. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000;10:803-8. 74 Klausen IC, Nielsen FE, Hegedus, et al. Treatment of hypothyroidism reduces low-density lipoproteins but not lipoprotein(a). Metabolism 1992;41:911-4. 75 Arem R, Escalante DA, Arem N, et al. Effect of L thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a). Metabolism 1995;44:1559-63. Clin Endocrinol 1995;43:445-9.a). Clin Chem 2000;46:1956-67. 76 Monzani F, Del Guerra P, Caraccio N, et al. Subclinical hypothyroidism: neurobehavioral features and beneficial effect of L-thyroxine treatment. Clinical Investigator 1993;71:367-71 77 Various authors. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13; 1-126. 78 Wardle CA, Fraser WD, Squire CR. Pitfalls in the use of thyrotropin concentration as a first-line thyroid-function test. Lancet 2001;357:1013-4 79 Surks MI, Sievert R. Drugs and thyroid function. N Engl J Med 1995; 333:1688-94. 80 Borst GC, Osburne RC, O'Brian JT, et al. Fasting decreases thyrotropin responsiveness to thyrotropin-releasing hormone: a potential cause of misinterpretation of thyroid function tests in the critically ill. J Clin Endocrinol Metab 1983; 57:380-3 81 Hamblin PS, Dyer SA, Mohr VS, et al. Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. J Clin Endocrinol Metab 1986; 62:717-22. 82 Spencer CA, Eigen A, Duda M et al. Sensitive TSH tests ? specificity limitations for screening for thyroid disease in hospitalized patients. Clin Chem 1987; 33: 1391-6. 83 Stockigt JR. Free thyroid hormone measurement: a critical appraisal. Endocr Metab Clin N Am 2001; 30: 265-89. 84 Stockigt JR. Guidelines for diagnosis and monitoring of thyroid disease: nonthyroidal illness. Clin Chem 1996;42:188-92. 85 Hein MD, Jackson IMD. Review: thyroid function in psychiatric illness. Gen Hosp Psychiat 1990; 12:232-44. 86 White AJ, Barraclough B. Thyroid disease and mental illness: a study of thyroid disease in psychiatric admissions. J Psychomatic Res 1988; 32:99-106. 87 MacDonald LA,Sackett DL, Haynes RB et al. Labelling in hypertension, a review of the behavioural and psychological consequences. J Chron Dis 1984; 37:933-42. 88 Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978; 299:926-30. 89 Weetman AP. Hypothyroidism: screening and subclinical disease. Br Med J 1997; 314;1175-8.89a Meier C, Trittibach P, Guglielmetti M et al. Serum thyroid stimulating hormone in assessment of the severity of tissue hypothyroidism in patients with overt thyroid failure: cross sectional survey Br Med J 2003; 326: 311-2. 90 Nordyke RA, Reppun TS, Madanay LD, et al. Alternative sequences of thyrotropin and free thyroxine assays for routine thyroid function testing. Arch Intern Med 1998;158:266-72 91 Snyder PJ, Utiger RD. Inhibition of thyrotropin response to thyrotropin-releasing hormone by small quantities of thyroid hormones. J Clin Invest 1972;51:2077-84 92 Vagenakis AG, Rapoport B, Azizi F, et al. Hyperresponse to thyrotropin-releasing hormone accompanying small decreases in serum thyroid hormone concentrations. J Clin Invest 1974;54:913-8 93 Meier CA, Maisey MN, Lowry A,et al. Interindividual differences in the pituitary-thyroid axis influence the interpretation of thyroid function tests. Clin Endocrinol 1993;39:101-7 94 Meikle AW, Stringham JD, Woodward MG, et al.. Hereditary and environmental influences on the variation of thyroid hormone in normal male twins. J Clin Endocrinol Metab 1988;66:588-92 95 Andersen S, Pedersen K, Bruun NH et al. Narrow individual variation in serum T4 and T3 in normal subjects: a clue to the understanding of subclinical thyroid disease J Clin Endocrinol Metab 2002; 87: 1068-72. 96 Weeke J, Gundersen HJ, Circadian and 30 minute variations in serum TSH and thyroid hormones in normal subjects. Acta Endocrinol 1978; 89:659-72. 97 Lewis GF, Alessi CA, Imperial JG, et al. Low serum free thyroxine index in ambulating elderly is due to a resetting of the threshold of thyrotropin feedback suppression. J Clin Endocrinol Metab 1991;73:843-9 98 Kabadi UM, Cech R. Normal thyroxine and elevated thyrotropin concentrations: evolving hypothyroidism or persistent euthyroidism with reset thyrostat. J Endocrinol Invest 1997;20:319-26 99 Fischer HRA, Hackeng WHL, Schopman W, Silberbusch J. Analysis of factors in hyperthyroidism, which determine the duration of suppressive treatment before recovery of thyroid stimulating hormone secretion. Clin Endocrinol 1982; 16: 575-85. 100 Amino N, Mori H, Iwatani Y, et al. High prevalence of transient post-partum thyrotoxicosis and hypothyroidism. N Engl J Med 1982;306:849-52 101 Orgiazzi J. Anti-TSH receptor antibodies in clinical practice. Endocrinol Metab Clin N Am 1999; 29: 339-55. 102 Pekary AE, Jackson IM, Goodwin TM, et al Increased in vitro thyrotropic activity of partially sialylated human chorionic gonadotropin extracted from hydatidiform moles of patients with hyperthyroidism J Clin Endocrinol Metab 1993; 76:70-4. 103 Brenta G, Schnitman M, Fretes O et al. Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or trithyroacetic acid J Clin Endocrinol Metab 2003; 88: 5287-92. 104 Re RN, Kourides IA, Ridgeway EC, Weintraub BD, Maloof F. The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. J Clin Endocrinol Metab 1976;43:338-46. 105Van den Berghe G, de Zegher F, Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clin Endocrinol 1994;41:731-7. 106 Martino E, Bartalena L, Bogazzi F, et al. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22: 240-54. in Endocrinol 1982; 16: 575-85. 107 Sato T, Suzuki Y, Taketani T, et al. Age-related change in pituitary threshold for TSH release during thyroxine replacement therapy for cretinism. J Clin Endocrinol Metab 1977;44:553-9. 108 Van Sande J, Parma J, Tonacchera M, et al. Somatic and germline mutations of the TSH receptor gene in thyroid disease. J Clin Endocrinol Metab 1995;80:2577-85. 109 Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 1993;14:348-99. 110 Smith PJ, Surks MI. Multiple effects of diphenylhydantoin on the thyroid hormone system. Endocr Rev 1984;5:514-24. 111 Bonomi M, Proverbio MC, Weber G et al. Hyperplastic pituitary gland, high serum glycoprotein hormone alpha subunit, and variable circulating TSH levels as hallmark of central hypothyroidism due to mutations of the TSH beta gene. J Clin Endocrinol Metab 2001; 86: 1600-4 112 Oliviera JHA, Persani L, Beck-Peccoz P et al. Investigating the paradox of high serum TSH levels in Sheehan's syndrome: characterization of TSH carbohydrate content and bioactivity. J Clin Endocrinol Metab 2001; 86: 1694-9. 113 Kahn BB, Weintraub BD, Csako G, Zweig MH. Factitious elevation of thyrotropin in a new ultrasensitive assay: implications for the use of monoclonal antibodies in "sandwich" immunoassay. J Clin Endocrinol Metab 1988;66:526-33. 114 Stockigt JR, Transport protein variants. In: Endocrinology, L DeGroot, JL Jameson eds. Saunders, Philadelphia, 4th Edn, 2001, 1603-8. 115 Sakata S, Nakamura S, Miura K. Autoantibodies against thyroid hormones or iodothyronine. Ann Intern Med 1985;103:579-89.116 Stockigt JR. Thyroid hormone binding. In: Endocrinology, L DeGroot, JL Jameson eds. Saunders, Philadelphia, 4th Edn, 2001, 1314-9. 117 Mendel CM, Frost PH, Kunitake ST, Cavalieri RR. Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma. J Clin Endocrinol Metab 1987;65:1259-64. 118 Jaume JC, Mendel CM, Frost PH, et al Extremely low doses of heparin release lipase activity into the plasma and can thereby cause artifactual elevations in the serum-free thyroxine concentration as measured by equilibrium dialysis. Thyroid 1996;6;79-83. 119 Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem 1996;42:140-5. 120 Mariotti S, Barbesino G, Caturegli P, et al. Complex alteration of thyroid function in healthy centenarians J Clin Endocrinol Metab 1993; 77: 1130-4 121 Verheecke P. Free triiodothyronine concentration in serum of 1050 euthyroid children is inversely related to their age. Clin Chem 1997;43:963-7. 122 Wiersinga WM, Nonthyroidal illness. In: Werner and Ingbar's The Thyroid. LE Braverman, RD Utiger eds. Lippincott Williams &Wilkens, Philadelphia, 8th Edn, 2000: 281-95. 123 Lim VS, Zavata DC,Flanigan MJ et al. Basal oxygen uptake: a new technique for an old test. J Clin Endocrinol Metab 1986; 62: 863-8. 124 Sarne DH, Refetoff S, Rosenfield R et al. Sex hormone-binding globulin in the diagnosis of peripheral resistance to thyroid hormone: the value of changes after short-term triiodothyronine administration. J Clin Endocrinol Metab 1988; 66:740-6. 125 Yotsumoto H, Imai Y, Kuzuya N, et al Increased levels of serum angiotensin converting enzyme in hyperthyroidiuism. Ann Intern Med 1982; 86: 326-8. 126 Takamatsu J, Majima M, Miki K et al. Serum ferritin as a marker of thyroid hormone action on peripheral tissues. J Clin Endocrinol Metab 1985; 61: 672-6. 127 Stockigt JR, Stevens V, White EL, Barlow JW. "Unbound analog" radioimmunoassays for free thyroxin measure the albumin-bound hormone fraction. Clin Chem 1983; 29: 1408-10. 128 Surks MI, Defesi CR: Normal free thyroxine concentrations in patients treated with phenytoin or carbamazepine: a paradox resolved. JAMA 1996; 275: 1495-8 129 Law LK, Cheung CK, Swaminathan R. Falsely high thyroxine results by fluorescence polarization in sera with high background fluorescence. Clin Chem 1988;34:1918-20. 130 Ritter D, Stott R, Grant N, Nahm NH. Endogenous antibodies that interfere with thyroxine fluorescence polarization assay but not with radioimmunoassay or EMIT. Clin Chem 1993;39: 508-11. 131 Beck-Peccoz P, Romelli PB, Cattaneo MG et al. Evaluation of free T4 methods in the presence of iodothyronine autoantibodies. J Clin Endocrinol Metab 1984;58:736-9. 132 Despr 閟 N, Grant AM. Antibody interference in thyroid assays: a potential for clincial misinformation. Clin Chem 1998;44:440-54. 133 Norden AGW, Jackson RA, Norden LE, et al: Misleading results from immunoassays of serum free thyroxine in the presence of rheumatoid factor. Clin Chem 1997; 43: 957-62. 134 Beck-Peccoz P, Persani L. Variable biological activity of thyroid-stimulating hormone. Europ J Endocrinol 1994;131: 331-40. 135 Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996;17:610-38. 136 Davey R. Thyroxine, thyrotropin, and age in a euthyroid hospital patient population. Clin Chem 1997;43:2143-8. 137 Caldwell G, Kellett HA, Gow SM, et al. A new strategy for thyroid function testing. Lancet 1985; 4: 1117-9. 137a Beckett GJ, Toft AD First-line thyroid function tests-TSH alone is not enough Clin Endocrinol 2003; 56; 20-1. 138 Ekins RP Measurement of free hormones in blood Endocr Rev 1990; 9: 5-46. 139 Braverman LE. Evaluation of thyroid status in patients with thyrotoxicosis. Clin Chem 1996; 42: 174-8. 140 Takamatsu J, Kuma K, Mozai T. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease. J Clin Endocrinol Metab 1986;62: 980-3. 141 Sobrinho LG, Limbert ES, Santos MA. Thyroxine toxicosis in patients with iodine induced thyrotoxicosis. J Clin Endocrinol Metab 1977;45:25-9. 142 Amino N, Yabu Y, Miki Y, et al. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis. J Clin Endocrinol Metab 1981;53:113-6. 143 Bartalena L, Pinchera A. Levothyroxine suppressive therapy: harmful and useless or harmless and useful? J Endocrinol Invest 1994;17:675-6. 144 Lum SM, Nicoloff JT, Spencer CA, et al. Peripheral tissue mechanisms for maintenance of serum triiodothyronine values in a thyroxine-deficient state in man. J Clin Invest 1984; 73: 570-5. 145 Docter R, Krenning EP, de Jong M, et al. The sick euthyroid syndrome: changes in thyroid hormone serum parameters and thyroid hormone metabolism. Clin Endocrinol 1993; 39:499-518. 146 Spencer CA, Schwarzbein D, Guttler RB, et al. Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and fourth generation TSH assays. J Clin Endocrinol Metab 1993;76:494-8 147 Laurberg P. Persistent problems with the specificity of immunometric TSH assays. Thyroid 1993; 3: 279-83. 148 Morley JE, Neuroendocrine control of thyrotropin secretion. Endocr Rev 1981; 2: 396-436. 149 Staub J-J, Noelpp B, Grani R, et al. The relationship of serum thyrotropin (TSH) to the thyroid hormones after oral TSH-releasing hormone in patients with preclinical hypothyroidism. J Clin Endocrinol Metab 1983; 56:449-53. 150 Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocr Metab 2001; 86: 1447-63. 150a Pacini F, Fugazzola L, Lippi F et al Detection of thyroglobulin in fine needle aspirates of non-thyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer 1992; 74:1401-4. 150b Knudsen N, B 黮 ow I, Jorgensen T et al. Serum Tg - a marker of thyroid abnormalities and iodine deficiency in epidemiological studies J Clin Endocrinol Metab 2001; 86: 3599-603. 151 Mariotti S, Caturegli P, Piccolo P, et al. Antithyroid peroxidase autoantibodies in thyroid diseases. J Clin Endocrinol Metab 1990;71:661-9. 152 Lazarus JH The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid 1998; 8; 909-13. 153 Murakami T, Masumoto T, Michitaka K, et al. Prediction of interferon 朼 lpha-induced thyroid dysfunction in patients with chronic hepatitis C. J Gastro Hepat 1995; 10: 528-31. 154 Lazarus JH, Hall R, Othman S, et al. The clinical spectrum of postpartum thyroid disease. Q J Med 1996; 89: 429-35. 155 Pop VJ, Maartens LH, Leusink G, et al. Are autoimmune thyroid dysfunction and depression related ? J Clin Endocrinol Metab 1998;83:3194-7. 156 Costagliola S, Morgenthaler NG, Hoermann R, et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease J Clin Endocrinol Metab 1999; 84:90-7. 157 Laurberg P, Nygaard B, Glinoer D, et al. Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. Europ J Endocrinol 1998;139:584-6. 158 Michelangeli V, Poon C, Taft J, et al. The prognostic value of thyrotropin receptor antibodymeasurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 1998; 8: 119-24. 159 Burmeister LA, Reverse T3 does not reliably differentiate hypothyroid sick syndrome from euthyroid sick syndrome. Thyroid 1995; 5: 435-41. 160 Hollander CS, Mitsuma T,Nihei N, et al Clinical and laboratory observations in cases of triiodothyronine toxicosis confirmed by radioimmunoassay. Lancet 1970; 1: 609-11 161 Sterling K, Refetoff S, Selenkow H. T3 thyrotoxicosis. Thyrotoxicosis due to elevated serum triiodothyronine levels. JAMA 1970; 213:571-5. 162 Lum SMC, Kaptein EM, Nicoloff JT Influence of nonthyroidal illnesses on serum thyroid hormone indices in hyperthyroidism. West J Med 1983;128:670-3. 163 Inada M, Sterling K: Thyroxine transport in thyrotoxicosis and hypothyroidism J Clin Invest 1967;46:1442-50. 164 Nauman JA, Nauman A, Werner SC: Total and free triiodothyronine in human serum. J Clin Invest 1967;46:1346-55. 165 Homsanit M, Sriussadaporn S, Vannasaeng et al Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism. Clin Endocrinol 2001;545:385-90. 166 Davies PH, Franklyn JA, Daykin J et al. The significance of TSH values measured in a sensitive assay in the follow-up of hyperthyroid partients treated with radioiodine. J Clin Endocrinol Metab 1992; 74: 1189-94. 167 Rothwell PM, Udwadia ZF, Lawler PG. Thyrotropin concentration predicts outcome in critical illness. Anaesthesia 1993;48:373-6. 168 Fraser WD, Biggart EM, O'Reilly DStJ, et al. Are biochemical tests of thyroid function of any value in monitoring patients receiving thyroxine replacement? Br Med J 1986;293:808-10 169 Ross DS, Daniels GH, Gouveia D. The use and limitations of a chemiluminescent TSH assay as a single thyroid function test in an outpatient endocrine clinic. J Clin Endocrinol Metab 1990;71:764-9. 170 Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism and bioavailability of levothyroxine in the treatment of hypothyroidism. N Engl J Med 1987; 316; 764-70. 170a Ferretti E, Persani L, Jaffrain-Rea ML et al. Evaluation of adequacy of levothyroxine replacement in patients with central hypothyroidism J Clin Endocrinol Metab 1999; 84:924-9. 171 Ain KB, Pucino F, Shiver TM, Banks SM. Thyroid hormone levels affected by time of blood sampling in thyroxine-treated patients. Thyroid 1993; 3:81-5. 172 Surks MI, Schadlow AR, Oppenheimer JH. A new radioimmunoassay for plasma L-triiodothyronine: measurements in thyroid disease and in patients maintained on hormonal replacement. J Clin Invest 1972; 51:3104-13. 173 Larsen PR, Thyroid-pituitary interaction: feedback regulation of thyrotropin secretion by thyroid hormones. N Engl J Med 1982; 306:23-32. 174 Roti E, Minelli R, Gardini E, et al. The use and misuse of thyroid hormone. Endocr Rev 1993; 14: 401-23. 175 DeGroot LG Dangerous dogmas in medicine: the non-thyroidal illness syndrome. J Clin Endocrinol Metab 1999; 84:151-64. 176 Sapin R, Schlienger J-L, Gasser F et al: Intermethod discordant free thyroxine measurements in bone marrow-transplanted patients. Clin Chem 2000;46:418-22. 177 Van den Berghe G. Novel insights into the neuroendocrinology of critical illness. Eur J Endocrinol 2000; 143;1-13. 178 Van den Berghe G, Wouters P, Weekers F et al: Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone releasing peptides and thyrotropin releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999; 84: 1311-23. 178a Siraj Es, Gupta MK, Reddy SS Raloxifene causing malabsorption of levothyroxine Arch Intern Med 2003; 163: 1367-70. 179 Stevenson HP, Archbold GPR, Johnston P, et al Misleading serum free thyroxine results during low molecular weight heparin treatment. Clin Chem 1998;44;1002-7. 180 Hawkins RC. Furosemide interference in newer free thyroxine assays. Clin Chem 44:2550, 1998 181 Spencer CA, LoPresti JS, Patel A, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab 1990;70:453-60. 182 Franklyn JA, Black EG, Betteridge J et al. Comparison of second and third generation methods for measuring serum thyrotropin in patients receiving thyroxine and in those with nonthyroidal illness. J Clin Endocrinol Metab 1994; 78: 1368-71. 183 Guimaraes V, DeGroot LJ, Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing. Thyroid 1996; 6;69-73. 184 Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337: 888-96. 185 Maxon HR, Smith HS, Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin N Am 1990; 19:685-717. 186 Cailleux AF, Baudin E, Travagli et al. Is diagnostic I-131 scanning useful after total thyroid ablation for differentiated thyroid cancer ? J Clin Endocrinal Metab 2000; 85: 175-8. 186a Wartofsky L, et al. Management of low risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin Thyroid 2002; 12: 583-90. 186b Weightman DR, Mallick UK, Fenwick JD et al. Discordant serum thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma: correlation with clinical outcome after 3 years of follow-up Cancer 2003; 98:41-7. 186c Pacini F, Molinaro M, Castagna MG et al Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma J Clin Endocrinol Metab 2003; 88: 3668-73. 186d Frasoldati A, Pesenti M, Gallo M et al Diagnosis of neck recurrences in patients with differentiated thyroid cancer Cancer 2003; 97: 90-6. 187 Chopra IJ, Solomon DH, Huang T-S. Serum thyrotropin in hospitalized psychiatric patients: evidence for hyperthyrotropinemia as measured by an ultrasensitive thyrotropin assay. Metabolism 1990;39:538-43. 188 Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 1997;18:404-33. 188a Ball R, Freedman DB, Holmes JC et al. Low normal concentrations of free thyroxin in serum in late pregnancy: physiological fact, not technical artefact. Clin Chem 1989; 35: 1891-6. 189 Roti E, Gardini E, Minelli R et al. Thyroid function evaluation by different commercially available free thyroid hormone measurement kits in term pregnant women and their newborns. J Endocrinol Invest 1991; 14: 1-9. 190 Osathanondh R, Tulshinsky D, Chopra IJ, Total and free thyroxine and triiodothyronine in normal and complicated pregnancy. J Clin Endocrinol Metab 1976; 42:98-104. 191 Bartalena L. Thyroid hormone-binding proteins: Update 1994. Endocrine Reviews Monographs. 3. Clinical and Molecular Aspects of Diseases of the Thyroid. Braverman LE, Refetoff S, eds. The Endocrine Society 1994;140-2. 192 Blackett PR, Fry H, Garnica A, Blick K. Thyroxine and triiodothyronine autoantibodies in Hashimoto's thyroiditis with severe hormone-resistant hypothyroidism. J Ped Endocrinol 1994;7:65-8. 193 Pearce CJ, Himsworth RL. Total and free thyroid hormone concentrations in patients receiving maintenance replacement treatment with thyroxine. Br Med J 1984;288:693-5. 194 Kew MC. Thyroxine binding globulin, hyperthyroxinemia and hepatocellular carcinoma. Hepatology 1991;13:808-9 195 Maye P, Bisetti A, Burger A, et al. Hyperprealbuminemia, euthyroid hyperthyroxinemia, Zollinger-Ellison-like syndrome and hypercorticism in a pancreatic endocrine tumour. Acta Endocrinol (Copenh) 1989;120:87-91. 196 Mori M, Amino N, Tamaki H, Miyai K, Tanizawa O. Morning sickness and thyroid function in normal pregnancy. Obstet Gynecol 1988;72:355-9. 197 Newnham HH, Hamblin PF, Long F, et al. Effect of oral frusemide on diagnostic indices of thyroid function. Clin Endocrinol 1986; 26: 423-31. 198 Chopra IJ, Hershman JM, Hornabrook RW. Serum thyroid hormone and thyrotropin levels in subjects from endemic goiter regions of New Guinea. J Clin Endocrinol Metab 1975;40:326-33.199 Inada M, Nishikawa M, Kawai I. Hypothyroidism associated with positive results of the perchlorate discharge test in elderly patients. Am J Med 1983;74:1010-5. 200 Covinsky M, Laterza O, Pfeifer JD et al. An IgM antibody to eschericia coli produces false positive results in multiple immunometric assays. Clin Chem 2000; 46:1157-61. 201 Kailajarvi M, Takala T, Gronroos P et al. Reminders of drug effects on laboratory test results. Clin Chem 2000; 46:1395-1400. 201a Ismail AAA, Walker PL, Cawood ML et al Interference in immunoassay is an underestimated problem Ann Clin Biochem 2002; 39: 366-73. 202 Kricka LJ, Interferences in immunoasay ?still a threat. Clin Chem 2000; 46:1037-8.